keeping up with covid - one company's story“

CFO, Treasurer and Senior VP Finance

"Keeping Up With COVID -One Company's Story“Harriss Currie

complexity simplified. 2

LUMINEX CORPORATION: FULLY EMBEDDED IN GLOBAL BIOMEDICAL SCIENCE AND HEALTHCARE ENTERPRISES

Actionable solutions across the biomedical spectrumLuminex is a biotech company providing molecular, proteomic, and cellular analysis tools and tests to life science and diagnostics markets exceeding $12B per year.

We seek to enable labs around the world to quickly advance science and deliver

beneficial, cost-effective healthcare solutions


LUMINEX CORPORATION: WHO WE ARE

• Differentiated platforms and assays, supported by 850+ patents, to address the needs of our clinical, biopharmaceutical, and research customers

• Enabling molecular, proteomic and cellular analysis

DIVERSIFIED SOLUTIONS

• Serving a growing $12B+ global life science marketplace

• Flexibility in reaching customers through direct sales, strategic partnerships, and other channels

ATTRACTIVE MARKETS

• Healthy profitability, increasing quarterly dividend, consistent cash flow and strong balance sheet

• ~25,000 instruments worldwide driving 75% annuity revenue

FINANCIAL STRENGTH & GLOBAL REACH


WE HELP LABS OBTAIN ANSWERS TO CHALLENGING MEDICAL QUESTIONS BY PROVIDING SOLUTIONS FOR DIAGNOSTIC AND RESEARCH PURPOSES.

OUR STORY

2001 2005 2007200019991995

2021

2009 2010

2019

2008

202020162015201320122011 2017

Luminex Corporation Founded

Austin, TX

Luminex® 100™Launched

Luminex CorporationGoes Public

First xMAP® ProductIVD Cleared

Luminex® 200™ Launched

xTAG® CysticFibrosis KitsIVD Cleared

TM BioscienceAcquisition

xTAG® RespiratoryViral Panel

IVD ClearedFLEXMAP 3D®

LaunchedMAGPIX®

Launched

Eragen Biosciences Acquisition

GenturaDxAcquisition

xTAG GastrointestinalPathogen Panel

xTAG® CYP2D6 &CYP2C19 Assays

IVD Cleared

ARIES® SystemARIES® HSV 1&2 Assay

IVD Cleared

NxTAG® Respiratory Pathogen

Panel IVD Cleared

ARIES® M1 SystemARIES® Flu A/B & RSV Assay

IVD Cleared

Nanosphere Inc. Acquisition

ARIES® Bordetella AssayARIES® C. difficile Assay

ARIES® GBS AssayARIES® Group A Strep

IVD Cleared

ARIES® Norovirus CE-IVD Cleared

Acquisition of MiliporeSigma'sImage-Based

Flow Cytometry Portfolio

ARIES® MRSA Assay IVD Cleared

NxTAG CoV Extended Panel (EUA)

VERIGENE® II System IVD Launch; xMAP® INTELLIFLEX

System RUO Launch;Multiple Additional SARS-

CoV-2 Assay Launches

ARIES® SARS-CoV-2 Assay (EUA)xMAP® SARS-CoV-2

Multi-Antigen IgG Assay (EUA)


DEVELOPING SOLUTIONS DURING THE COVID -19 PANDEMIC

PCR-BASED TESTS

5

• Two Luminex PCR-based COVID-19 tests have already received EUA clearance

• Run on ARIES and NxTAGSystems

• Expecting EUA clearance on NxTAG RPP+SARS-CoV-2 Assay any day

• ARIES A/B & RSV + SARS-CoV-2 Assay EUA submission is ready to go to FDA

• Planning for EUA submission to FDA for VERIGENE II RSP Flex Assay later this quarter

ANTIBODY-BASED TESTS

• xMAP Multi-Antigen IgG assay has received EUA clearance

• Developing additional antibody tests to help identify individuals who may have some level of immunity to the virus

• Anticipate submitting EUA submission to FDA for xMAP-based Neutralization Assay in Q2 ‘21


MULTIPLE COVID-19 SOLUTIONS FOR THE LONG RUN

Note: Figures are total assay and system revenue

Molecular Testing

Serology Testing

Vaccines/ Therapeutics/ Cell Research

L O N G T E R M :

ARIES® • Targeted, sample-to-answer diagnostic testing

VERIGENE® • Syndromic, sample-to-answer diagnostics and surveillance

MAGPIX®

• Syndromic, high-throughput, cost-effective diagnostic testing

• SARS-CoV-2 serology testing for immunity monitoring, vaccine development

LUMINEX® 200™

FLEXMAP 3D®

• High-throughput, multiplex serology, cytokine & proteomic research

xMAP®

INTELLIFLEX

• High-throughput, multiplex serology research

• Vaccine, therapeutic, cytokine & proteomic research

S H O R T / M I D - T E R M : R E S E A R C H , T H E R A P E U T I CS A N D V A C C I N E S H E L P L O W ER T H E C U R V E

D I A G N O S T I C S A N D S E R O LO GY H E L P F L A T T E N T H E C U R V E


SARS-CoV-2 MDx PROJECTS

VERIGENE® II RSP Flex + SARS-CoV-2 (EUA)• Built on RP Flex panel• 3 gene CoV target add to PCR

tube 4• Finalizing submission package

VERIGENE® II RSP Flex + SARS-CoV-2 (RUO) • Launch planned for Q2 ‘21

VERIGENE® II RSP Flex + SARS-CoV-2 (CE-IVD)• Launch planned for Q3 ‘21

VERIGENE® SARS-CoV-2 (EUA)• Pooling claim (5 samples)• LoD of 100 copies/ml• Submitted in Jan ‘21• Reprioritized by FDA

* Biosurveillance recommendations

NxTAG® RPP v2 (IVD)• Includes updated Flu and other

targets*• Submitting for EUA in March

ARIES® SARS-CoV-2 Assay (EUA, CE-IVD and LDT)

NxTAG® CoV Extended PanelNxTAG® RPP+SARS-CoV-2 (CE-IVD)

VERIGENE® SARS-CoV-2 AssayNxTAG® RPP + SARS-CoV-2 Panel

ARIES® Flu A/B & RSV + SARS-CoV-2 (EUA)• Uses Taqman for improved

MFG• Submitting for EUA 2/25

ARIES® Flu + SARS-CoV-2 Fast• Tech Feasibility underway for

~60-75 min version


xMAP® SARS-CoV-2 MULTI-ANTIGEN IgG ASSAY

Detects IgG antibodies against 3 SARS-CoV-2 antigens, providing comprehensive results:

• S1 subunit of the spike protein

• Receptor Binding Domain (RBD) of the spike protein

• Nucleocapsid protein


EXPANDED MANUFACTURING TO MEET INCREASED DEMAND

Chicago/VERIGENE®

• ~25% increase in footprint ($8M facility purchase). Q1 2021

• 600K test capacity (VERIGENE II fully automated lines)

• 1.2M test capacity (VERIGENE I)

• $3.4M total investment (already paid)

Madison/Reagents

• 10%+ increase in building footprint (investment of $2.5M)

• Supports both ARIES® and VERIGENE II

Austin/ARIES®

• 600K test capacity. Beginning of 2020

• 1.6M test capacity. Summer 2020

• 3.2M test capacity (investment of ~$5M). Ready now!

• 4.5M test capacity (investment of $1M). Mid-2021

• 6M+ test capacity (investment of ~$5M). Beginning of 2022

• 50K sq ft facility expansion. Mid-2021

Toronto/NxTAG®

• 1M test capacity. Beginning of 2020

• 9M test capacity (investment of $500K). Summer 2020

Questions?

keeping up with covid - one company's story“

Documents